|Bid||32.27 x 900|
|Ask||34.50 x 1100|
|Day's range||31.57 - 34.22|
|52-week range||19.51 - 73.72|
|Beta (5Y monthly)||1.81|
|PE ratio (TTM)||365.98|
|Earnings date||03 Aug 2020 - 07 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||62.22|
Investors in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) had a good week, as its shares rose 4.9% to close at...
Thank you for joining us today to discuss Arrowhead's results for its fiscal second quarter ended March 31, 2020. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, Chief Medical Officer who will discuss our clinical programs; Dr. Curt Bradshaw, our Chief Scientific Officer who will discuss our discovery, platform development and manufacturing efforts; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials.
It hasn't been the best quarter for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders, since the share price...
Arrowhead files to begin Phase 1/2a study of ARO-ENaC, RNAi therapeutic for Cystic Fibrosis
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This report will, first...
Arrowhead dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD for alcohol related and nonalcohol related liver diseases